BiotechTube

JS001 + nab-paclitaxel + Cisplatin + Carboplatin

Phase 2Recruiting
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Esophageal Small Cell Carcinoma

Conditions

Esophageal Small Cell Carcinoma

Trial Timeline

Nov 17, 2020 → Dec 31, 2026

NCT ID
NCT05173246

About JS001 + nab-paclitaxel + Cisplatin + Carboplatin

JS001 + nab-paclitaxel + Cisplatin + Carboplatin is a phase 2 stage product being developed by Sun Pharmaceutical for Esophageal Small Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05173246. Target conditions include Esophageal Small Cell Carcinoma.

What happened to similar drugs?

19 of 20 similar drugs in Esophageal Small Cell Carcinoma were approved

Approved (19) Terminated (2) Active (1)
✅rabeprazole and pantoprazoleEisaiApproved
✅rabeprazole + pantoprazoleEisaiApproved
✅Placebo + CisaprideJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅EsomeprazoleAstraZenecaApproved
✅EsomeprazoleAstraZenecaApproved
✅EsomeprazoleAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05173246Phase 2Recruiting

Competing Products

20 competing products in Esophageal Small Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
39
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
39
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
47
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
39
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPhase 1
29
FamotidineAstellas PharmaPhase 2/3
38
ASP546CAstellas PharmaPhase 1/2
39
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
28
E3810 + E3810 + PlaceboEisaiPhase 3
40
Rabeprazole ER + RanitidineEisaiPhase 3
40